Pasithea Therapeutics - Warrants (11/08/2026) EBIT

The latest EBIT for KTTAW is $-8B as of March 2026. That compares with $-11B in the prior-year period — up 24.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Pasithea Therapeutics - Warrants (11/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, KTTAW's EBIT moved from $-11B to $-8B — a 24.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pasithea Therapeutics - Warrants (11/08/2026)'s operating scale or balance-sheet position.

Against Healthcare companies, KTTAW currently prints $-8B for EBIT, while the sector average sits near $23B. That is roughly 134.6% below the sector mean. Large gaps often invite a closer look at Pasithea Therapeutics - Warrants (11/08/2026)'s growth, margins, and balance sheet.

A EBIT figure of $-8B for KTTAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting KTTAW's EBIT ($-8B), review year-over-year change from $-11B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.